HDAC11 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL28250	0.57	14/20
SCHEMBL29476	0.57	14/20
SCHEMBL31064	0.57	14/20
SCHEMBL30259	0.57	14/20
Vorinostat (SCHEMBL9018)	1.00	13/20
SCHEMBL28328	0.61	13/20
SCHEMBL28329	0.61	13/20
SCHEMBL28330	0.61	13/20
SCHEMBL29695	0.61	13/20
SCHEMBL30199	0.61	13/20
Iodipamide (SCHEMBL37678)	0.41	13/20
SCHEMBL34229	0.51	12/20
SCHEMBL19539	0.48	10/20
Trichostatin (SCHEMBL19886)	1.00	9/20
SCHEMBL28840	0.61	9/20
SCHEMBL28841	0.61	9/20
SCHEMBL28842	0.61	9/20
SCHEMBL29955	0.61	9/20
SCHEMBL29956	0.61	9/20
SCHEMBL21138	0.49	9/20

Clinical trials — most relevant to HDAC11 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
Voronistat in Pediatric Patients With Drug Resistant Epilepsy	PHASE2	UNKNOWN
Chidamide Combined With Toripalimab in Sarcoma	PHASE2	COMPLETED
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma	PHASE2	COMPLETED
Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma	PHASE2	RECRUITING
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer	PHASE2	UNKNOWN
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab	PHASE1/PHASE2	RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas	PHASE2	ACTIVE_NOT_RECRUITING
Vorinostat in Children	PHASE1/PHASE2	COMPLETED
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma	PHASE2	COMPLETED
Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART	PHASE1/PHASE2	COMPLETED
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours	PHASE1	COMPLETED
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors	PHASE1	COMPLETED
Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia	PHASE1	COMPLETED
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction	PHASE1	COMPLETED
Safety and Pharmacokinetic Profile of CKD-581	PHASE1	COMPLETED
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome	nan	UNKNOWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia	nan	RECRUITING
Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer	nan	WITHDRAWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Chi-GVM Regimen for the Treatment of R/R PTCL	nan	UNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Imaging Histone Deacetylase in the Heart	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a HDAC11 binder may also engage these)

Protein	Name	Similarity
Q9GKU5	—	1.000	Q9GKU5 →
Q91WA3	—	0.999	Q91WA3 →
Q7SXM0	—	0.966	Q7SXM0 →
B1H369	—	0.966	B1H369 →
Q6GPA7	—	0.954	Q6GPA7 →
Q923S8	—	0.947	Q923S8 →
Q94EJ2	—	0.944	Q94EJ2 →
Q5R5F8	—	0.944	Q5R5F8 →
Q80YV4	—	0.944	Q80YV4 →
B4G0F3	—	0.942	B4G0F3 →
Q64323	—	0.942	Q64323 →
Q5R962	—	0.941	Q5R962 →
Q4R4U1	—	0.941	Q4R4U1 →
Q9SSP5	—	0.941	Q9SSP5 →
Q2R483	—	0.940	Q2R483 →
Q9CWH5	—	0.940	Q9CWH5 →
Q9NVE7	—	0.940	Q9NVE7 →
Q5R514	—	0.940	Q5R514 →
Q9HD40	—	0.940	Q9HD40 →
E0CSI1	—	0.940	E0CSI1 →
P37287	—	0.940	P37287 →
Q9FN41	—	0.939	Q9FN41 →
Q9MT28	—	0.939	Q9MT28 →
Q05B63	—	0.939	Q05B63 →
Q99797	—	0.939	Q99797 →
Q5F477	—	0.938	Q5F477 →
C6JS30	—	0.938	C6JS30 →
Q5VNW5	—	0.938	Q5VNW5 →
Q9D020	—	0.938	Q9D020 →
B9N1F9	—	0.938	B9N1F9 →